Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

A recent study unveils how stromal interaction molecule 1 (STIM1), a protein involved in calcium signaling, plays a pivotal ...

Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of ...

With his research group "Chromatin and SUMO Physiology," the molecular biologist has shown that the chemotherapeutic agent sorafenib actively remodels skeletal muscle cells and thus triggers cachexia.

The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant overall survival benefits.

Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib significantly improved ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the European Commission (EC) to treat hepatocellular carcinoma (HCC), the most common type of ...